28 November 2022 in The Journal of V. N. Karazin Kharkiv National University, Series "Medicine"
Introduction. Adropin is a hormone that is involved in the pathogenesis of arterial hypertension (AH) and diseases of the cardiovascular system and energy homeostasis, in particular, it reduces insulin resistance by controlling glucose synthesis in the liver. Aim. To investigate the level of adropin and its interaction with risk factors for AH in overweight and obese patients. Materials and methods. 70 patients with AH and overweight or obesity aged 62.4 ± 10.4 years were examined. 10 practically healthy people were selected for the control group. The level of adropin was determined by enzyme immunoassay (Finetest Elisa Kit) in blood serum. The inclusion criteria for participation in the study were: age of patients 40–75 years; arterial hypertension; BMI > 25 kg/m2. Results. It was established that the average level of adropin in patients with AH and comorbid obesity or excess body weight (n = 70) was 775.5 ± 311.7 pg/ml, which is significantly lower than the content of this peptide in practically healthy individuals (n = 10), which was 1084.6 ± 110.2 pg/ml (p < 0.01). A tendency towards a decrease in the level of the hormone in men was noted. It is probably associated with a much higher prevalence of smoking among this category of people, since when assessing the factors contributing to the development of AH and worsening its prognosis, a significant decrease in adropin was found in persons with a history of smoking (p < 0.01). In obese patients (BMI > 30 kg/m2), the level of adropin was significantly lower (p < 0.05), as well as in individuals with blood pressure > 150/90 mm Hg (p > 0.05). Conclusions. The level of serum adropin is significantly reduced in persons with AH and overweight and obesity compared to practically healthy persons. Factors contributing to a decrease in peptide concentration include smoking, obesity, and elevated blood glucose levels. Blood pressure indicators are not critical for changes in blood hormone concentration, which is probably due to medications used to treat AH.
27 June 2017 in Current Issues in Pharmacy and Medical Sciences
The results of treatment of patients with arterial hypertension and obesity combined with non-alcoholic steatohepatitis are presented in article. Herein, the combined use of olmesartan or telmisartan with atorvastatin for 12 weeks had a positive impact on the physical condition of patients with arterial hypertension and obesity. This effect was manifested by maintenance of optimal blood pressure, the reduction of subjective complaints and the improvement of heart hemodynamics. Administration of sartans and statins to patients with arterial hypertension combined with obesity and non-alcoholic steatohepatitis led to a significant reduction of LDL (p<0.01) and LDL cholesterol levels (p<0.01), as well as the values of leptin (p<0.01) and IL-6 (p<0.01). The combination of olmesartan or telmisartan with atorvastatin not only allows a control of BP, but also a reduction of the pro-atherogenic fractions of blood lipids, hyperleptinaemia and levels of pro-inflammatory IL-6, hence, in this manner, improving the patient general condition.
1 December 2023 in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Background:: The constant increase of arterial hypertension and the development of pathology at an earlier age are global healthcare problems that cause damage to vital organs and worsen patient prognosis. In recent years, studies have shown that galectin-3 plays a role in the development and progression of arterial hypertension and coronavirus disease (COVID-19). Objective:: The explanatory research study aimed to analyze the prognostic value of galectin-3 de-termination in the serum blood and lymphocytes of patients with arterial hypertension and corona-virus disease (COVID-19). Methods:: The patients were divided into two groups: Group 1 consisted of 36 individuals with AH, Group 2 included 35 patients with arterial hypertension and polysegmental COVID-19 pneumonia, and 16 practically healthy individuals were included in the control group. All patients underwent anthropometry, biochemical blood analysis, determination of galectin-3, level in serum and lym-phocytes, IL-1β, IL-6, and echocardiography. Results:: The highest level of galectin-3 was found in patients of Group 1, while in patients of Group 2, the concentration of galectin-3 was significantly decreased, mostly due to the treatment of COVID-19, in addition to prolonged antihypertensive therapy. Conclusion:: The level of galectin-3 in serum and lymphocytes was significantly higher in patients of both groups compared to the control group (p<0.05). Arterial hypertension causes structural changes in the cardiovascular system that are associated with elevated levels of galectin-3 in serum and lymphocytes. It can be used as a marker of myocardial damage in the context of arterial hyper-tension and COVID-19.
6 May 2025 in EMERGENCY MEDICINE
Background. The main cardiovascular risk factors have been investigated over the past few decades. Key factors include dyslipidemia, high blood pressure, smoking, diabetes mellitus and obesity. According to research data, it is important to examine the significance of the homeostasis model of insulin resistance (HOMA-IR) in the Ukrainian population, particularly among individuals with cardio-metabolic risk factors that lead to the development of atherosclerotic, non-atherosclerotic cardiovascular diseases and metabolic complications. Materials and methods. One hundred and ninety-nine individuals were examined: 152 patients with stage I–II arterial hypertension (AH) and 47 individuals without any previously diagnosed diseases. All patients were stratified into six groups according to the number of components of metabolic syndrome (MetS): group 0 — no components of MetS (12 practically healthy individuals); group 1 — the presence of 1 component of MetS; group 2 — the presence of 2 components of MetS; group 3 — three-component MetS; group 4 — four-component MetS; group 5 — five-component MetS. Results. The involvement of a higher number of MetS components was associated with an increase in the IR marker — HOMA-IR. With an increase in the number of MetS components, the body mass index, waist circumference (WC), uric acid and glycemia indicators increased linearly. The incidence of prediabetes, hyperuricemia and AH increased linearly with an increase in the components of MetS. AH and abdominal obesity were early manifestations of metabolic changes. The statistical differences in cardiometabolic risk are more significant when the HOMA-IR exceeded 1.78. When the threshold was exceeded, a significant increase in WC, ttriglycerides, uric acid and C-reactive protein was found in the observed patient groups, and with HOMA-IR values > 3.89, the probability of detecting MetS signs significantly increases. Conclusions. With an increase in the components of MetS, even at the stage of its formation, an increase in the insulin resistance index — HOMA-IR was observed. Abdominal obesity and AH are the most common manifestations at the stage of MetS formation. The average HOMA-IR value of 3.89 aligns with the criteria of MetS, while HOMA-IR above 1.78 is associated with a significance of cardio-metabolic risk factors such as WC, triglycerides, uric acid and C-reactive protein.
20 June 2025 in Proceeding of the Shevchenko Scientific Society. Medical Sciences
Introduction. Soluble suppression of tumorigenicity 2 (sST2) and galectin-3 are considered markers of myocardial hypertrophy and fibrosis. Changes in their concentrations are observed in cardiovascular diseases, including arterial hypertension. The aim. To determine threshold values of hypertrophy and fibrosis biomarkers, namely sST2 and galectin-3, in patients with arterial hypertension. Materials and methods. A prospective study was conducted on 82 patients with arterial hypertension (AH). Patients were stratified into two groups based on left ventricular mass index (LVMI) values: Group 1 with left ventricular hypertrophy (LVMI > 115 g/m² for men and 90 g/m² for women, n=33) and Group 2 with normal LVMI values (n=27). Results. Patients with left ventricular hypertrophy exhibited significantly elevated sST2 and galectin-3 levels. Direct correlations were observed between LVMI and sST2 values (r=0.6397; p=0.000) and galectin-3 (r=0.5113; p=0.001). Both biomarkers correlated with various cardiac parameters, including interventricular septal thickness at end-diastole, left atrial diameter, left ventricular end-diastolic diameter, and posterior wall thickness at end-diastole (specifically with sST2). With a selected sST2 value of 17.0 ng/ml, the diagnostic method demonstrated 88.33% accuracy, 92.59% specificity, 93.3% positive predictive value, and 83.33% negative predictive value for hypertrophy. At the chosen galectin-3 level of 29.0 ng/ml, the proposed method achieved 72.22% accuracy, 73.68% sensitivity, 70.59% specificity, 73.68% positive predictive value, and 70.59% negative predictive value. In conclusion, measuring sST2 and galectin-3 biomarkers facilitates the evaluation of left ventricular hypertrophy, serving as an additional tool in assessing cardiac dysfunction and indicating diverse developmental pathways.